Jump to content

Arie Lev Gruzman

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 12:54, 14 April 2023 (Alter: issn. | Use this bot. Report bugs. | Suggested by Abductive | #UCB_webform 2164/3850). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Arie Lev Gruzman
Born(1970-10-03)October 3, 1970
Nizhny Novgorod, Russia
CitizenshipIsraeli
Alma materthe Hebrew University of Jerusalem
Scientific career
FieldsMedicinal chemistry, Peptidomimetic chemistry, Pharmacology
InstitutionsBar Ilan University
Doctoral advisorShlomo Sasson, Jehoshua Katzehendler
Other academic advisorsVishvanath Lingappa (California Pacific Medical Center)

Arie Lev Gruzman (Template:Lang-he; born 3 October 1970) is a professor of chemistry at Bar Ilan University specializing in Medicinal Chemistry.

Biography

Arie Lev Gruzman[1] (1970) was born in Gorky (nowadays Nizhniy Novgorod), Russia. He graduated (1988) from First Gorky Nursing College [ru][2] (Summa cum Laude) as a practical nurse. At the same year, he enrolled at the Pediatric faculty of Gorky Academy for Medicine (nowadays, Privolzhsky Research Medical University). After two and a half years, he interrupted his education towards M.D. and repatriated to Israel in 1991. He obtained his B.Sc. in Medicinal chemistry from Bar-Ilan University (1995) and a Ph.D. (summa cum laude) from the School of Pharmacy,[3] Faculty of Medicine, at the Hebrew University of Jerusalem under the supervision of Prof. Shlomo Sasson and Prof. Jehoshua Katzehendler. After a military service in the IDF, he was a postdoctoral researcher (2004–2007) at the Department of Physiology, University of California, San Francisco School of Medicine (UCSF) and at California Pacific Medical Center (CPMC) at San Francisco, under the supervision of Prof. Vishvanath Lingappa.[4] After returning to Israel, he worked as a head of a project (development of new antidiabetic drug) at Yissum Research Development Company of the Hebrew University. Since 2009 he is a faculty member in the department of chemistry at Bar-Ilan University.[5] Gruzman served as a vice-president of the Medicinal Chemistry Section of the Israel Chemical Society MCS-ICS (2011–2015).[6] He is also one of the founders of the startup drug development company “AltA-ZuZ”.[7]

Scientific interests and publications

His research areas of interest[1][8] include organic synthesis, medicinal chemistry, peptide chemistry, analytical chemistry, pharmacology, pharmacokinetics studies, in vitro and in vivo drug candidate testing, nanotechnology, molecular computer-aided modeling, and basic biochemistry. His current research[9] focuses on developing of new drugs for the treatment of insulin dependent diabetes mellitus (IDDM, Type 1 diabetes)[10] and non-insulin dependent diabetes mellitus (NIDDM, Type 2 diabetes) type of diabetes.[11][12][13] His group, together with collaborators, developed several compounds that have a bi-functional mode of action in NIDDM. Such drug candidates increase the rate of glucose uptake in skeletal muscles and augment the rate of insulin secretion.[14][15] Gruzman's group also developed new drug candidates against ALS.[16][17][18] His chemistry expertise is mainly related to peptide/peptidomimetic chemistry.[19][20] [21][22]

Among his awards is Excellence in teaching[23] (2016); “Faculty of 1000 Biology Award” (2007);[24] The Kaye Innovation Awards at the Hebrew University of Jerusalem (2003);[25] Bern-Schlander Research Award, the Diabetes Research Centre of the Hebrew University of Jerusalem (2002). He was elected as Israeli Representative of the Chemistry and Human Health, Division of International Union of Pure and Applied Chemistry (IUPAC) for the term 2022–2023.

References

  1. ^ a b Prof. Arie-Lev Gruzman, Bar-Ilan University
  2. ^ Nowadays, (Template:Lang-ru)
  3. ^ "School of Pharmacy, The Hebrew University of Jerusalem". Archived from the original on 2016-03-11. Retrieved 2018-11-27.
  4. ^ Vishwanath Rao Lingappa - The American Society for Clinical Investigation
  5. ^ Department of Chemistry, Bar-Ilan University
  6. ^ MCS-ICS Medicinal Chemistry Section of the Israel Chemical Society
  7. ^ AltA-ZuZ Therapeutics
  8. ^ Prof. Gruzman's lab - website
  9. ^ Prof. Arie-Lev Gruzman - List of Publications
  10. ^ Munder, Anna; Israel, Liron L.; Kahremany, Shirin; Ben-Shabat-Binyamini, Rina; Zhang, Charles; Kolitz-Domb, Michal; Viskind, Olga; Levine, Anna; Senderowitz, Hanoch; Chessler, Steven; Lellouche, Jean-Paul; Gruzman, Arie (2017). "Mimicking Neuroligin-2 Functions in β-Cells by Functionalized Nanoparticles as a Novel Approach for Antidiabetic Therapy". ACS Applied Materials & Interfaces. 9 (2): 1189–1206. doi:10.1021/acsami.6b10568. ISSN 1944-8244. PMC 6035049. PMID 28045486.
  11. ^ Gruzman, Arie; Hidmi, Adel; Katzhendler, Jehoshua; Haj-Yehie, Abdalla; Sasson, Shlomo (2004). "Synthesis and characterization of new and potent α-lipoic acid derivatives". Bioorganic & Medicinal Chemistry. 12 (5): 1183–1190. doi:10.1016/j.bmc.2003.11.025. ISSN 0968-0896. PMID 14980629.
  12. ^ Gruzman, Arie; Shamni, Ofer; Ben Yakir, Moriya; Sandovski, Daphna; Elgart, Anna; Alpert, Evgenia; Cohen, Guy; Hoffman, Amnon; Katzhendler, Yehoshua; Cerasi, Erol; Sasson, Shlomo (2008). "Noveld-Xylose Derivatives Stimulate Muscle Glucose Uptake by Activating AMP-Activated Protein Kinase α". Journal of Medicinal Chemistry. 51 (24): 8096–8108. doi:10.1021/jm8008713. ISSN 0022-2623. PMID 19049348.
  13. ^ Meltzer-Mats, Ella; Babai-Shani, Gali; Pasternak, Lily; Uritsky, Neta; Getter, Tamar; Viskind, Olga; Eckel, Jürgen; Cerasi, Erol; Senderowitz, Hanoch; Sasson, Shlomo; Gruzman, Arie (2013). "Synthesis and Mechanism of Hypoglycemic Activity of Benzothiazole Derivatives". Journal of Medicinal Chemistry. 56 (13): 5335–5350. doi:10.1021/jm4001488. ISSN 0022-2623. PMID 23750537.
  14. ^ Pasternak, L.; Meltzer-Mats, E.; Babai-Shani, G.; Cohen, G.; Viskind, O.; Eckel, J.; Cerasi, E.; Sasson, S.; Gruzman, A. (2014). "Benzothiazole derivatives augment glucose uptake in skeletal muscle cells and stimulate insulin secretion from pancreatic β-cells via AMPK activation". Chem. Commun. 50 (76): 11222–11225. doi:10.1039/C4CC03310H. ISSN 1359-7345. PMID 25116279.
  15. ^ Rozentul, Naomi; Avrahami, Yosef; Shubely, Moran; Levy, Laura; Munder, Anna; Cohen, Guy; Cerasi, Erol; Sasson, Shlomo; Gruzman, Arie (2017). "A Novel Phenylchromane Derivative Increases the Rate of Glucose Uptake in L6 Myotubes and Augments Insulin Secretion from Pancreatic Beta-Cells by Activating AMPK". Pharmaceutical Research. 34 (12): 2873–2890. doi:10.1007/s11095-017-2271-7. ISSN 0724-8741. PMID 28983714. S2CID 29665991.
  16. ^ Gruzman, A.; Wood, W. L.; Alpert, E.; Prasad, M. D.; Miller, R. G.; Rothstein, J. D.; Bowser, R.; Hamilton, R.; Wood, T. D.; Cleveland, D. W.; Lingappa, V. R.; Liu, J. (2007). "Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis". Proceedings of the National Academy of Sciences. 104 (30): 12524–12529. Bibcode:2007PNAS..10412524G. doi:10.1073/pnas.0705044104. ISSN 0027-8424. PMC 1941502. PMID 17636119.
  17. ^ Daniel, Bareket; Green, Omer; Viskind, Olga; Gruzman, Arie (2013). "Riluzole increases the rate of glucose transport in L6 myotubes and NSC-34 motor neuron-like cells via AMPK pathway activation". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 14 (5–6): 434–443. doi:10.3109/21678421.2013.808226. ISSN 2167-8421. PMID 23834207. S2CID 24461128.
  18. ^ Getter, Tamar; Zaks, Ilana; Barhum, Yael; Ben-Zur, Tali; Böselt, Sebastian; Gregoire, Simpson; Viskind, Olga; Shani, Tom; Gottlieb, Hugo; Green, Omer; Shubely, Moran; Senderowitz, Hanoch; Israelson, Adrian; Kwon, Inchan; Petri, Susanne; Offen, Daniel; Gruzman, Arie (2015). "A Chemical Chaperone-Based Drug Candidate is Effective in a Mouse Model of Amyotrophic Lateral Sclerosis (ALS)". ChemMedChem. 10 (5): 850–861. doi:10.1002/cmdc.201500045. ISSN 1860-7179. PMID 25772747. S2CID 39170185.
  19. ^ Shapira, Renana; Rudnick, Safra; Daniel, Bareket; Viskind, Olga; Aisha, Vered; Richman, Michal; Ayasolla, Kamesh R.; Perelman, Alex; Chill, Jordan H.; Gruzman, Arie; Rahimipour, Shai (2013). "Multifunctional Cyclic d,l-α-Peptide Architectures Stimulate Non-Insulin Dependent Glucose Uptake in Skeletal Muscle Cells and Protect Them Against Oxidative Stress". Journal of Medicinal Chemistry. 56 (17): 6709–6718. doi:10.1021/jm4005225. ISSN 0022-2623. PMID 23984871.
  20. ^ Trifonov, Lena; Afri, Michal; Palczewski, Krzysztof; Korshin, Edward E.; Gruzman, Arie (2018). "An Expedient Synthesis of CMF-019: (S)-5-Methyl-3-({)1-(pentan-3-yl)-2- (thiophen-2-ylmethyl)-1H-benzo[d]imidazole-5-carboxamido)hexanoic Acid, a Potent Apelin Receptor (APJ) Agonist". Medicinal Chemistry. 14 (7): 688–694. doi:10.2174/1573406414666180412154952. ISSN 1573-4064. PMC 6993063. PMID 29651942.
  21. ^ Kahremany, Shirin; Babaev, Ilana; Hasin, Pinhas; Tamir, Tigist Y.; Ben-Zur, Tali; Cohen, Guy; Jiang, Zhengyu; Weintraub, Sagiv; Offen, Daniel; Rahimipour, Shai; Major, M. Ben; Senderowitz, Hanoch; Gruzman, Arie (2018). "Computer-Aided Design and Synthesis of 1-{4-[(3,4-Dihydroxybenzylidene)amino]phenyl}-5-oxopyrrolidine-3-carboxylic Acid as an Nrf2 Enhancer". ChemPlusChem. 83 (5): 320–333. doi:10.1002/cplu.201700539. ISSN 2192-6506. PMID 31957349.
  22. ^ Kahremany, Shirin; Zhenin, Michael; Shenberger, Yulia; Maimoun, David; Colotti, Gianni; Arad, Michael; Shainberg, Asher; Senderowitz, Hanoch; Ruthstein, Sharon; Gruzman, Arie (2018). "Peptide-based development of PKA activators". New Journal of Chemistry. 42 (23): 18585–18597. doi:10.1039/C8NJ01732H. ISSN 1144-0546.
  23. ^ Bar-Ilan University Excellence in Teaching, 2016
  24. ^ F1000 website
  25. ^ The Kaye Innovation Awards, Hebrew University of Jerusalem
Retrieved from "https://en.wikipedia.org/w/index.php?title=Arie_Lev_Gruzman&oldid=1149790883"